The activity of interleukin-11 in the gastrointestinal tract

Current Opinion in Critical Care

Volumn 6, Issue 2, 2000, Pages 148-152

  Opal, Steven M ^a,c   Keith Jr , James C ^b  

^a BROWN UNIVERSITY   (United States)

^b PFIZER INC   (United States)

^c MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; INTERLEUKIN 11; RECOMBINANT INTERLEUKIN 11;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; CELL LINE; CRITICAL ILLNESS; CYTOKINE PRODUCTION; CYTOTOXICITY; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM ULCER; DRUG MECHANISM; INTESTINE CELL; INTESTINE RESECTION; MOUSE; NONHUMAN; RAT; REVIEW; SHORT BOWEL SYNDROME;

EID: 0033942884     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075198-200004000-00012     Document Type: Review

References (32)

1. 1 Schwertschlag US, Trepiccio WL, Dykstra KH, Keith Jr JC, Turner KJ, Dorner AJ: Hematopoietic, immunomodulatory, and epithelial effects of interleukin-11. Leukemia 1999, 13:1307-1315. This is an update of the current status of the preclinical and clinical research into the activity of IL-11 in health and disease. The potential utility of this multifunctional cytokine in critical illness as an anti-inflammatory agent and epithelial support growth factor is reviewed.
2. 2 Keith Jr JC: Interleukin-11. In The cytokine reference: a compendium of cytokines and other mediators of the host defense. Edited by Oppenheim J, Feldman M. San Diego: Academic Press 1999, 6:1-58. This is a definitive review of the entire published database regarding interleukin-11 up to the present. The paper is a part of an online publication that reviews all the available literature on the cytokines. This is an excellent reference source on IL-11 biology.
3. 3 Grosfeld JL, Du X, Williams DA: Interleukin-11: its biology and prospects for clinical use. J Parenter Enteral Nutr 1999, 23:S67-69. This brief review describes the evidence that supports the use of IL-11 after various forms of gastrointestinal injury and the potential utility of IL-11 after massive small bowel resections in the management of short bowel syndrome.
4. 4 Neddermann P, Graziani R, Ciliberto G, Paonessa G: Functional expression of soluble of human interleukin-11 (IL-11) receptor-α and stoichiometry of in vitro IL-11 receptor complexes with gp130. J Biol Chem 1996, 271:30986-30991.
5. 5 Barton VA, Hudson KR, Heath JK: Identification of three distinct receptor binding sites for murine interleukin-11. J Biol Chem 1999, 274:5755-5761. The three-dimensional structure of murine IL-11 has been resolved. The molecule has a basic 4 alpha bundle structure similar to several other cytokines and growth factors. There are three major contact points with its cellular receptor: the IL-11 alpha receptor site, the primary GP130 binding site, and a secondary GP130 receptor binding site. It is assumed that the human IL-11 structural interactions with its receptor are similar to the murine system. Confirmation of the human IL-11: IL-11Rα/GP130 receptor interaction awaits crystallization and analysis of the three-dimensional structure human IL-11.
6. 6 Nundurkar HH, Robb L, Tarliton D, Barnett L, Koentgen F, Begley CG: Adult mice with targeted mutation with interleukin-11 receptor (IL-11Rα) display normal hematopoiesis. Blood 1997, 90:2148-2159.
7. 7 Robb L, Li R, Hartley L, Nandurkar HH, Koentgen F, Begley CG: Infertility in female mice lacking the receptor for interleukin-11 is due to a defective uterine response to implantation. Nat Med 1998, 4:303-308. Interleukin-11 receptor alpha knockout mice are infertile owing defective implantation and formation of decidua tissue formation. Interleukin-11 is not necessary for normal hematopoiesis but it is absolutely essential for normal fertility.
8. 8 Pflanz S, Tachen I, Grotzinger J, Jacques I, Dahmen H, Heinrich PC, Mueller-Newen G: A fusion protein of interleukin-11 and soluble interleukin-11 receptor acts as a superagonist on cells expressing gp130. FEBS Lett 1999, 450:117-122. A fusion peptide consisting of IL-11 and soluble IL-11 alpha receptor activates GP130 bearing cells. This study confirms that IL-11 signaling occurs in the absence of membrane bound IL-11Rα.
9. 9 Bozza N, Kyvelos D, Trepicchio WL, Collins M, Klempner NS, Dorner AJ: Recombinant human interleukin-11 does not affect functions of purified human neutrophils in vitro. J Interferon Cytokine Res 1998, 18:889-895. Neutrophils are not affected by the anti-inflammatory actions of IL-11 because the IL-11 alpha receptor is not expressed on the cellular surface of polymorphonuclear cells. In this respect, IL-11 differs from IL-10, which will downregulate neutrophil expression of pro-inflammatory cytokines.
10. 10 Endo S, Inada K, Arakawa N, Yamada Y, Nakae H, Takakuwa T, Namiki M, Inoue Y, Shimamura T, Suzuki T, Taniguchi S, Yoshida M: Interleukin-11 levels in patients with disseminated intravascular coagulation. Res Commun Mol Pathol Pharmacol 1996, 99:253-256.
11. 11 Hermann JA, Hall ME, Maini RN, Feldmann M, Brennan FM: Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. Arthritis Rheum 1998, 41:1388-1397. Endogenous IL-11 was detected in the blood and the synovial fluid in patients with rheumatoid arthritis. Interleukin-11 acts in synergy with IL-10 to limit TNF and IL-1 synthesis by rheumatoid synovial fibroblasts.
12. 2 production. Nonsteroidal anti-inflammatory drugs block IL-11 in synovial cells from patients with rheumatoid arthritis.
13. 13 Trepicchio WL, Wang LL, Bozza M, Dorner AJ: Interleukin-11 regulates macrophage effector function through the inhibition of nuclear factor-κB. J Immunol 1997, 159:5661-5670.
14. 14 Hill GR, Crawford JM, Keith JC Jr: Interleukin-11 effects in acute graft-vs.-host-disease: role of Th2 polarization, gastrointestinal protection and inflammatory cytokine inhibition. J Clin Invest 1998, 102:115-123. Interleukin-11 was highly beneficial in a murine model of graft versus host disease after allogeneic bone marrow transplantation. Interleukin-11 prevented mucosal injury from graft versus host disease, reduced systemic endotoxin levels, promoted Th2 polarization, and attenuated interferon-γ levels after bone marrow transplant.
15. 15 Sonis S, Edwards L, Lucey C: The biological basis for the attenuation of mucositis: the example of interleukin-11. Leukemia 1999, 13:831-834. This paper reviews the problem of chemotherapy and/or radiation therapy-induced mucositis and the morbidity associated with mucous membrane damage in the treatment of malignant diseases. The authors describe the therapeutic rationale for clinical trials with interleukin-11 as a preventative strategy against mucositis after treatment with cytotoxic agents.
16. 16 Peterson RL, Bozza MN, Dorner AJ: Interleukin-11 induces intestinal epithelial growth arrest through effects of retinoblastoma protein phosphorylation. Am J Pathol 1996, 149:895-902.
17. 17 Booth C, Potten CS: Effects of IL-11 on the growth of intestinal epithelial cells in vitro. Cell Prolif 1995, 28:581-594.
18. 18 Waxman AB, Einarsson O, Seres T, Knickelbein RG, Homer R, Warshaw JB, Johnston R, Elias JA: Targeted lung expression of interleukin-11 enhances murine tolerance of 100% oxygen and diminishes hyperoxia-induced DNA fragmentation. Chest 1999, 86:340-348. Using a transgenic mouse model with targeted over-expression of IL-11 within lung tissue, these investigators were able to demonstrate the epithelial protective effects of IL-11 after oxidant injury to pulmonary tissues. The findings indicate that the protective effects of IL-11 against damage to gastrointestinal epithelial tissues extend to the pulmonary mucous membranes as well.
19. 19 Teicher B, Chen Y, Ara G, Emi Y, Kakeji Y, Maehara Y, et al.: Interaction of interleukin-11 with cytotoxic therapies in vitro against CEM cells and in vivo against EMT-6 murine mammary carcinoma. Int J Cancer 1996, 67:864-870.
20. 20 Potten CS: Interleukin-11 protects the clonogenic stem cells in murine small intestinal crypts from impairment of their reproductive capacity by irradiation. Int J Cancer 1995, 62:356-361.
21. 21 Liu Q, Du XX, Schindel DT, Yang ZX, Rescorla FJ, Williams DA, Grosfeld JL: Trophic effects of interleukin-11 in rats with experimental short bowel syndrome. J Pediatr Surg 1996, 31:1047-1050.
22. 22 Fiore NF, Lediczky G, Liu Q, Orazi A, Du X, Williams DA, Grosfeld JL: Comparison of interleukin-11 and epidermal growth factor on residual small intestine after massive small bowel resection. J Pediatr Surg 1998, 33:24-29. After massive small bowel resection in a rat model, IL-11 had additive effects on small bowel growth potential with epidermal growth factor. Epidermal growth factor lead to generalized enterocyte and myocyte growth, whereas IL-11 acted upon enterocytes only. Interleukin-11 may prove to be efficacious in the clinical management of short bowel syndrome in patients after extensive small bowel resection.
23. 23 Sonis ST, Van Vugt AG, McDonald J, Dotoli E, Schwertschlag U, et al.: Mitigating effects of interleukin-11 on a consecutive courses of 5-fluorouracil-induced ulcerative mucositis in hamsters. Cytokine 1997, 9:605-612.
24. 24 Peterson RL, Wang L, Keith JC Jr, Dorner AJ: Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease. Lab Invest 1998, 78:1503-1512. In this transgenic rat model that mimics human inflammatory disease, IL-11 led to decreased disease activity and reduced colonic RNA expression of TNF, IL-1, and interferon-γ. These results provide additional preclinical support for the therapeutic use of IL-11 in patients with inflammatory bowel disease.
25. 25 Du X, Liu Q, Yang Z, Orazi A, Resorla FJ, Grosfeld JL, Williams DA: Protective effects of interleukin-11 in a murine model of ischemic bowel necrosis. Am J Physiol 1997, 272:G545-552.
26. 26 Castagliuolo I, Kelly CP, Qiu BS, Nikulasson ST, LaMont JE, Pothoulakis C: IL-11 inhibits Clostridium difficile toxin A enterotoxicity in rat ileum. Am J Physiol 1997, 273:G333-341.
27. 27 Keith JC Jr, Albert A, Sonis TS, Pfeiffer CJ, Schaub RB: Interleukin-11 a pleiotropic cytokine: exciting new effects of IL-11 on gastrointestinal mucosal biology. Stem Cells 1994, 12 (suppl 1):79-90.
28. 28 Schindel D, Maze R, Liu Q, Williams D, Grosfeld J: Interleukin-11 improves survival and reduces bacterial translocation and bone marrow suppression in burned mice. J Pediatr Surg 1997, 32:312-315.
29. 29 Opal SM, Jhung JW, Keith JC Jr, Goldman SJ, Palardy JE, Parejo NA: Additive effects of human recombinant interleukin-11 and granulocyte colony-stimulating factor in experimental gram-negative sepsis. Blood 1999, 93:3467-3472. This study examines the therapeutic value of a combination of granulocyte colony-stimulating factor with IL-11 in an experimental model of Pseudomonas aeruginosa sepsis in the neutropenic rat. The combination of G-CSF and IL-11 was significantly more effective than either cytokine given alone (P<0.001) in reducing the mortality rate from septic shock, and IL-11 (but not G-CSF) protected the gut epithelium from damage after the chemotherapy-induced period of neutropenia.
30. 30 Tepler I, Elias L, Smith JW, Hussein M, Rosen G, Chang AY-C, Moore JO, Gordon MS, Kuca B, Beach KJ, Loewry TW, Garnick MB, Kaye JA: A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996, 87:3607-3614.
31. 31 Aoyama K, Uchida T, Takanuki F, Usui T, Watanaba T, Higuchi S, Toyoki T, Mizogugchi H: Pharmacokinetics of recombinant human interleukin-11 (rhIL-11) in healthy male subjects. Br J Clin Pharmacol 1997, 43:571-578.
32. 32 Sands BE, Bank S, Sninsky CA, Robinson M, Katz S, Singleton JW, Miner PB, Safdi MA, Galandiuk S, Hanauer SB, Varilek GW, Buchman AL, Rodgers VD, Salzberg B, Cai B, Loewy J, DeBruin MF, Shapiro M, Schwertschlag US: Preliminary evaluation of recombinant human interleukin-11 in patients with active Crohn's disease. Gastroenterology 1999, 117:58-64. This clinical study is a phase IB/II dose-finding study where patients with active inflammatory bowel disease received subcutaneous injections of rhIL-11 for several weeks, and study participants were then followed for evidence of systemic toxicity and/or alterations in disease activity. The IL-11 treatment was well tolerated and appeared to have some measurable clinical benefits in the severity of symptoms in Crohn disease.